Veeva Systems

New Veeva Vault Submissions Publishing eLearning Application Speeds Employee Onboarding

Retrieved on: 
Monday, February 12, 2024
Publishing, DIA, Veeva Systems, Growth, Organization, Risk management

PLEASANTON, Calif., Feb. 12, 2024 /PRNewswire/ -- DIA RSIDM 2024 — Veeva Systems (NYSE: VEEV) today announced Veeva Vault Submissions Publishing eLearning, a new regulatory information management (RIM) application that educates users on key publishing processes for seamless development of compliant content. With on-demand process-based training, companies can quickly onboard employees to use Veeva Vault Submissions Publishing while increasing time to value.

Key Points: 
  • PLEASANTON, Calif., Feb. 12, 2024 /PRNewswire/ -- DIA RSIDM 2024 — Veeva Systems (NYSE: VEEV) today announced Veeva Vault Submissions Publishing eLearning , a new regulatory information management (RIM) application that educates users on key publishing processes for seamless development of compliant content.
  • With on-demand process-based training, companies can quickly onboard employees to use Veeva Vault Submissions Publishing while increasing time to value.
  • Vault Submissions Publishing eLearning provides employees with the resources to remain qualified and current with the latest features and techniques for efficient continuous publishing.
  • "Veeva Vault Submissions Publishing eLearning will help customers scale their publishing operations to keep pace with growth and market changes."

Veeva to Release Fiscal 2024 Fourth Quarter and Full Year Results on February 29, 2024

Retrieved on: 
Tuesday, February 6, 2024
Veeva Systems

PLEASANTON, Calif. , Feb. 6, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2024, after market close on February 29, 2024.

Key Points: 
  • PLEASANTON, Calif. , Feb. 6, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2024, after market close on February 29, 2024.
  • Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m.
  • Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m.
  • ET).

ODAIA Attracts Top Talent to Accelerate Next Phase of Innovation and Customer Success

Retrieved on: 
Tuesday, February 6, 2024
AI, Information management, IMS Health, News, NBA, B2B, IQVIA, ABM, Patient, Pandora, Data science, Veeva Systems, Marketing, HCP, Health, AvePoint, Software as a service, NHL, Medtech, Management

TORONTO, Feb. 6, 2024 /PRNewswire/ -- ODAIA today announced it expanded its strategic alliances, product management, and marketing leadership teams to help address customers' most strategic challenges in commercial operations. The company is bringing together accomplished life sciences industry experts and proven SaaS technology leaders to accelerate innovation and customer success in Customer Science, an emerging business discipline that integrates data science, behavioral science, and AI to drive healthcare professional (HCP) engagement.

Key Points: 
  • The company is bringing together accomplished life sciences industry experts and proven SaaS technology leaders to accelerate innovation and customer success in Customer Science , an emerging business discipline that integrates data science, behavioral science, and AI to drive healthcare professional (HCP) engagement.
  • The ODAIA Customer Science cloud solution, MAPTUAL , gives sales and marketing advanced, AI-driven insights and predictions for a comprehensive understanding of HCP prescribing patterns and behavioral trends.
  • ODAIA continues to attract top talent to drive the next phase of innovation in Customer Science and help advance pharma customers' commercial strategies.
  • He leads the development of ODAIA industry solutions and market strategy, as well as strategic relationships with customers and partners.

Now Available: Veeva Compass Suite of Commercial Data Products

Retrieved on: 
Tuesday, January 30, 2024
Intelligence, Forecasting, Injection, HCO, Prescription, Veeva Systems, HCP, Surveying

PLEASANTON, Calif., Jan. 30, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of the full Veeva Compass Suite of commercial data products for a more complete view into patient populations and HCP-level insight. Veeva Compass Prescriber and Veeva Compass National are the first to deliver projections for both retail prescriptions and complex procedures, including in-office administered therapies, injections, and infusions. Veeva Compass Suite also includes Compass Patient, granular, longitudinal patient data spanning prescriptions, procedures, and diagnoses. Veeva Compass products are licensed by the brand and give brands unlimited data access, including historical data.

Key Points: 
  • Complete suite of modern patient, prescriber, and national data products for today's complex therapies
    PLEASANTON, Calif., Jan. 30, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of the full Veeva Compass Suite of commercial data products for a more complete view into patient populations and HCP-level insight.
  • Veeva Compass Suite also includes Compass Patient , granular, longitudinal patient data spanning prescriptions, procedures, and diagnoses.
  • Veeva Compass products are licensed by the brand and give brands unlimited data access , including historical data.
  • "The availability of the full Veeva Compass Suite of data products is a major milestone for the industry and for Veeva," said Peter Stark, executive vice president and general manager, Veeva Compass.

Veeva Completes Study Migrations to Veeva Vault EDC for Top Biopharma

Retrieved on: 
Wednesday, January 17, 2024
Patient, EDC, Veeva Systems

PLEASANTON, Calif., Jan. 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a top 20 biopharma and Veeva Services migrated 25 ongoing clinical studies to Veeva Vault EDC from a legacy electronic data capture (EDC) application. This successful migration of an entire core study portfolio – including a large study with more than 500 research sites and 7,000 patients – is an important industry first. With migrations complete, the customer plans to use Vault EDC for all current and future trials globally.

Key Points: 
  • PLEASANTON, Calif., Jan. 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a top 20 biopharma and Veeva Services migrated 25 ongoing clinical studies to Veeva Vault EDC from a legacy electronic data capture (EDC) application.
  • With migrations complete, the customer plans to use Vault EDC for all current and future trials globally.
  • With this top 20 biopharma, Vault EDC was used to migrate more than 55 million data points and five million forms safely and efficiently.
  • "Biopharma companies can now reliably migrate ongoing studies from their legacy applications to Veeva Vault EDC with a repeatable approach that can reduce fees, drive standardization, and provide a better site experience."

Veeva Completes Study Migrations to Veeva Vault EDC for Top Biopharma

Retrieved on: 
Wednesday, January 17, 2024
Patient, EDC, Veeva Systems

BARCELONA, Spain, Jan. 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a top 20 biopharma and Veeva Services migrated 25 ongoing clinical studies to Veeva Vault EDC from a legacy electronic data capture (EDC) application. This successful migration of an entire core study portfolio – including a large study with more than 500 research sites and 7,000 patients – is an important industry first. With migrations complete, the customer plans to use Vault EDC for all current and future trials globally.

Key Points: 
  • BARCELONA, Spain, Jan. 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a top 20 biopharma and Veeva Services migrated 25 ongoing clinical studies to Veeva Vault EDC from a legacy electronic data capture (EDC) application.
  • With migrations complete, the customer plans to use Vault EDC for all current and future trials globally.
  • With this top 20 biopharma, Vault EDC was used to migrate more than 55 million data points and five million forms safely and efficiently.
  • "Biopharma companies can now reliably migrate ongoing studies from their legacy applications to Veeva Vault EDC with a repeatable approach that can reduce fees, drive standardization, and provide a better site experience."

Veeva to Present at Upcoming Investor Conference

Retrieved on: 
Tuesday, January 16, 2024
CFO, Conference, Veeva Systems

PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following virtual investor conference:

Key Points: 
  • PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following virtual investor conference:
    26th Annual Needham Growth Conference.
  • Brent Bowman, CFO, and Paul Shawah, EVP Commercial Strategy, are presenting on Friday, January 19, 2024, at 10:15 a.m. Eastern Time.
  • The presentation will be webcast.
  • Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com .

MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment

Retrieved on: 
Tuesday, January 9, 2024
Technology, Venture Capital, Professional Services, Software, Practice Management, Biotechnology, Health, Pharmaceutical, Data Management, ChromeOS, Patient, RWD, Research, Debiopharm, Software as a service, Pharmacist, Veeva Systems, Communication, Physician, Investment, Pharmaceutical industry

MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner.

Key Points: 
  • MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner.
  • The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
  • “We see significant synergies between MedaSystems and Debiopharm Innovation Fund.
  • "Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions.

MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment

Retrieved on: 
Tuesday, January 9, 2024
Health, Technology, Health Technology, Software, Clinical Trials, Pharmaceutical, ChromeOS, Patient, RWD, Research, Debiopharm, Software as a service, Pharmacist, Veeva Systems, Communication, Physician, Investment, Pharmaceutical industry

The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.

Key Points: 
  • The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
  • “We see significant synergies between MedaSystems and Debiopharm Innovation Fund.
  • "Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions.
  • Together, we look forward to crafting a future where every patient has timely access to the most promising therapies," said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.

Leading Pharma Adopts Veeva Vault Validation Management for Digital Validation Execution and Improved Efficiency

Retrieved on: 
Thursday, January 11, 2024
Central nervous system, Veeva Systems, CNS, Cryptocurrency

PLEASANTON, Calif., Jan. 11, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., a global biotech company, is using Veeva Vault Validation Management to streamline and accelerate their validation process. By adopting a validation solution with built-in best practices, the company can execute digital validation while centralizing data and improving visibility.

Key Points: 
  • SK Life Science builds off its success with Veeva Vault QualityDocs and Vault QMS to optimize validation management.
  • "As the industry continues to shift from traditional paper-based validation, more companies are advancing validation with Veeva Vault Validation Management to streamline and standardize processes," said Nina Ricciardelli, director, Veeva Vault Validation Management.
  • The company is building off its success with Veeva Vault QualityDocs and Veeva Vault QMS to optimize its validation programs, driving greater compliance and traceability across all systems.
  • For more on Veeva Vault Validation Management, visit: veeva.com/VaultValidationManagement
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems